On the basis of the abovementioned evidence, the aim of this study is to evaluate the effect of PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 on 303 mg of silybin-phospholipids complex, 10 μg of vitamin D, and 15 mg of vitamin E twice a day for 6 months administration in NAFLD patients. The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatotic liver disease.